The management of Type 2 Diabetes Mellitus in Bangladesh has long lacked robust real-world effectiveness data, despite rapid therapeutic advancements. The Emlino Exemplify Trial decisively addressed this unmet need, earning international recognition for its real-world clinical insights. Recently published in a leading European journal, the Emlino Exemplify Trial marks Emlino as Bangladesh’s one and only clinically tested combination of Empagliflozin and Linagliptin.
This landmark study, realized through the vision and collaboration of leading Bangladeshi endocrinologists in the spirit of “আমাদের দেশে আমাদের ট্রায়াল,” successfully translates cutting-edge research into real-world clinical experience.
A celebratory program brought together esteemed healthcare professionals from DMCH and BIRDEM, where Dr. Mirza Sharifuzzaman, principal investigator, presented the trial’s real-world outcomes, reinforcing physicians’ confidence in Emlino. The session was chaired by Prof. Faruque Pathan and graced by National Professor A. K. Azad Khan, both of whom lauded ACME’s DiaCare for its pioneering initiative in advancing diabetes research in Bangladesh.
The event also featured insights from leading figures including Dr. Faria Afsana, Prof. Hafizur Rahman, and other key opinion leaders, with over 100 endocrinologists engaging in robust discussion on the study’s impact.
The Emlino Exemplify Trial stands as a testament to clinical excellence in diabetes care, underscoring ACME’s DiaCare’s commitment to fostering trust, innovation, and world-class standards in Bangladesh’s healthcare landscape.
This landmark study, realized through the vision and collaboration of leading Bangladeshi endocrinologists in the spirit of “আমাদের দেশে আমাদের ট্রায়াল,” successfully translates cutting-edge research into real-world clinical experience.
A celebratory program brought together esteemed healthcare professionals from DMCH and BIRDEM, where Dr. Mirza Sharifuzzaman, principal investigator, presented the trial’s real-world outcomes, reinforcing physicians’ confidence in Emlino. The session was chaired by Prof. Faruque Pathan and graced by National Professor A. K. Azad Khan, both of whom lauded ACME’s DiaCare for its pioneering initiative in advancing diabetes research in Bangladesh.
The event also featured insights from leading figures including Dr. Faria Afsana, Prof. Hafizur Rahman, and other key opinion leaders, with over 100 endocrinologists engaging in robust discussion on the study’s impact.
The Emlino Exemplify Trial stands as a testament to clinical excellence in diabetes care, underscoring ACME’s DiaCare’s commitment to fostering trust, innovation, and world-class standards in Bangladesh’s healthcare landscape.